Azintuxizumab provides a monoclonal antibody platform for oncology and antibody research and specifically supports studies of antigen recognition, antibody-mediated cellular targeting, and antibody characterization. Researchers can use it to investigate target engagement and cellular responses in appropriate experimental models.
Key Features and Benefits
- SLAMF7-Targeting Antibody: Recognizes SLAMF7, also known as CS1 or CD319, a cell-surface protein expressed on plasma cells and certain immune cells.
- Monoclonal Antibody Platform: Provides an antibody specifically for investigating selective SLAMF7 recognition and cellular targeting.
- CS1 Antigen Recognition: Supports studies of SLAMF7 expression, antibody binding, and antigen-specific cellular interactions.
- Multiple Myeloma Targeting: Enables investigation of SLAMF7 as a tumor-associated antigen in malignant plasma cells.
- ADC Development Platform: Provides the antibody component associated with Azintuxizumab Vedotin (ABBV-838), an investigational SLAMF7-directed ADC.
- Cellular Internalization Research: Supports investigation of antibody uptake and intracellular trafficking in SLAMF7-expressing cells.
- Antibody Engineering Research: Especially useful for studying antibody conjugation, antigen recognition, and targeted payload delivery strategies.
Applications
- Multiple Myeloma Research: Supports investigation of SLAMF7-directed antibody targeting in multiple myeloma models.
- Plasma Cell Malignancy Research: Useful for studying CS1 expression and antibody recognition in malignant plasma cells.
- SLAMF7-Positive Cancer Research: Supports evaluation of antibody binding and cellular interactions in SLAMF7-expressing cancer models.
- Tumor Antigen Research: Enables studies of SLAMF7/CD319 expression and its role in plasma cell biology.
- ADC Research: Provides a targeting antibody platform specifically for investigating SLAMF7-directed payload conjugation and delivery.
- Antibody Binding Assays: Especially useful for evaluating antigen recognition, binding specificity, and antibody-cell interactions.
- Cellular Internalization Studies: Supports investigation of antibody uptake and intracellular trafficking in SLAMF7-expressing cells.
- Comparative Antibody Research: Useful for comparing SLAMF7-targeting antibodies and antibody-mediated plasma cell recognition strategies.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Azintuxizumab provides a SLAMF7-directed monoclonal antibody for investigating plasma cell antigen recognition and targeted cellular binding and specifically supports multiple myeloma, plasma cell malignancy, antibody engineering, and ADC research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
